• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SVP Fin. - Global Controller Smart Dalton E. Iii exercised 5,000 shares at a strike of $58.08 and sold $352,723 worth of shares (4,262 units at $82.76), increasing direct ownership by 10% to 7,778 units (SEC Form 4)

    4/29/25 4:04:40 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRK alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Smart Dalton E. III

    (Last) (First) (Middle)
    126 EAST LINCOLN AVENUE

    (Street)
    RAHWAY NJ 07065

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Merck & Co., Inc. [ MRK ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    SVP Fin. - Global Controller
    3. Date of Earliest Transaction (Month/Day/Year)
    04/25/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 04/25/2025 M 5,000 A $58.08 12,039.802 D
    Common Stock 04/25/2025 S 4,262 D $82.76 7,777.802(1) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $58.08 04/25/2025 M 5,000 05/01/2016(2) 04/30/2025 Common Stock 5,000 $0 0 D
    Explanation of Responses:
    1. Holdings include shares acquired in dividend reinvestment transactions.
    2. The option became exercisable in equal installments on 5/1/2016, 5/1/2017 and 5/1/2018.
    /s/ Kelly E. W. Grez, attorney-in-fact for Dalton Smart 04/29/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MRK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRK

    DatePrice TargetRatingAnalyst
    4/22/2025$85.00Neutral
    Cantor Fitzgerald
    2/18/2025$128.00 → $105.00Buy → Hold
    Deutsche Bank
    2/10/2025$121.00 → $100.00Buy → Hold
    TD Cowen
    1/8/2025$110.00Buy → Hold
    Truist
    12/20/2024$136.00 → $105.00Outperform → Market Perform
    BMO Capital Markets
    12/10/2024$121.00Buy
    BofA Securities
    12/4/2024$130.00Hold → Buy
    HSBC Securities
    11/15/2024Peer Perform
    Wolfe Research
    More analyst ratings

    $MRK
    SEC Filings

    See more
    • SEC Form 10-Q filed by Merck & Company Inc.

      10-Q - Merck & Co., Inc. (0000310158) (Filer)

      5/2/25 4:10:22 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Merck & Company Inc.

      144 - Merck & Co., Inc. (0000310158) (Subject)

      4/25/25 4:05:58 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merck & Company Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Merck & Co., Inc. (0000310158) (Filer)

      4/24/25 6:45:16 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal

      Paris, May 12, 2025 - Jeito Capital ("Jeito"), a global leading independent Private Equity fund dedicated to biopharma, is pleased to announce the promotion of Mehdi Ainouche to Partner and Julien Elric to Senior Principal. These promotions represent the next phase of Jeito's growth and reflect the continued strengthening of its team. They also underscore the firm's commitment to developing talent and supporting career progression from within. Mehdi Ainouche, PharmD, joined Jeito as Principal in 2020, shortly after the fund's inception and was promoted to Senior Principal in 2024. With over a decade of experience in life sciences investment, Mehdi has been instrumental across the full inve

      5/12/25 1:00:00 AM ET
      $BIIB
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Merck Animal Health and State of Kansas Announce $895 Million Investment in Manufacturing and Research & Development Facilities in De Soto

      Merck Animal Health unveils its largest economic development project in recent history Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), and Kansas Governor Laura Kelly jointly announced today the $895 million expansion of Merck Animal Health's manufacturing facility in De Soto, Kansas. The $895 million capital expansion will be constructed on an existing Merck-owned property that is the site of its biologics facility in De Soto, Kansas. It includes an $860 million investment in the site's existing manufacturing facility and a further $35 million investment in its research and development

      5/8/25 6:45:00 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merck to Participate in the Bank of America 2025 Global Healthcare Conference

      Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, Human Health U.S., and Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Bank of America 2025 Global Healthcare Conference on Wednesday, May 14, 2025, at 10:40 a.m. PDT / 1:40 p.m. EDT. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We

      5/7/25 6:45:00 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $MRK
    Financials

    Live finance-specific insights

    See more
    • SVP Fin. - Global Controller Smart Dalton E. Iii exercised 2,050 shares at a strike of $83.18 and covered exercise/tax liability with 844 shares, increasing direct ownership by 14% to 9,539 units (SEC Form 4)

      4 - Merck & Co., Inc. (0000310158) (Issuer)

      5/5/25 4:23:49 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP Fin. - Global Controller Smart Dalton E. Iii exercised 845 shares at a strike of $84.06 and covered exercise/tax liability with 290 shares, increasing direct ownership by 7% to 8,333 units (SEC Form 4)

      4 - Merck & Co., Inc. (0000310158) (Issuer)

      5/2/25 4:18:09 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, Human Health Int?l Romanelli Joseph exercised 4,325 shares at a strike of $83.95 and covered exercise/tax liability with 2,132 shares, increasing direct ownership by 11% to 22,946 units (SEC Form 4)

      4 - Merck & Co., Inc. (0000310158) (Issuer)

      5/2/25 4:14:57 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merck Announces First-Quarter 2025 Financial Results

      Total Worldwide Sales Were $15.5 Billion, a Decrease of 2% From First Quarter 2024; Excluding the Impact of Foreign Exchange, Sales Grew 1% KEYTRUDA Sales Grew 4% to $7.2 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 6% WINREVAIR Sales Were $280 Million Animal Health Sales Grew 5% to $1.6 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 10% GARDASIL/GARDASIL 9 Sales Declined 41% to $1.3 Billion; Excluding the Impact of Foreign Exchange, Sales Declined 40% GAAP EPS Was $2.01; Non-GAAP EPS Was $2.22 Presented Compelling Data From a Diverse Range of Programs, Including: Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Phase

      4/24/25 6:30:00 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call April 24

      Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its first-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, April 24. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Fre

      4/1/25 6:45:00 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results

      Fourth-Quarter Worldwide Sales Were $15.6 Billion, an Increase of 7% From Fourth Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 9% Fourth-Quarter GAAP EPS Was $1.48; Non-GAAP EPS Was $1.72; GAAP and Non-GAAP EPS Include a Charge of $0.23 per Share Related to Certain Business Development Transactions Full-Year Worldwide Sales Were $64.2 Billion, an Increase of 7% From Full Year 2023; Excluding the Impact of Foreign Exchange, Growth Was 10% KEYTRUDA Sales Grew 18% to $29.5 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 22% WINREVAIR Sales Were $419 Million Animal Health Sales Grew 4% to $5.9 Billion; Excluding the Impact of Foreign Exchange, S

      2/4/25 6:30:00 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Thulin Inge G bought $250,000 worth of shares (2,833 units at $88.25), increasing direct ownership by 2,833% to 2,933 units (SEC Form 4)

      4 - Merck & Co., Inc. (0000310158) (Issuer)

      2/7/25 4:09:51 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Baker Douglas M Jr bought $1,327,500 worth of shares (15,000 units at $88.50), increasing direct ownership by 1,500% to 16,000 units (SEC Form 4)

      4 - Merck & Co., Inc. (0000310158) (Issuer)

      2/7/25 4:04:52 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Merck & Company Inc. (Amendment)

      SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)

      2/13/24 4:55:49 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Merck & Company Inc. (Amendment)

      SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)

      2/9/23 10:54:48 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Merck & Company Inc. (Amendment)

      SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)

      2/9/22 3:15:54 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Merck with a new price target

      Cantor Fitzgerald initiated coverage of Merck with a rating of Neutral and set a new price target of $85.00

      4/22/25 8:01:38 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merck downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded Merck from Buy to Hold and set a new price target of $105.00 from $128.00 previously

      2/18/25 7:11:01 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merck downgraded by TD Cowen with a new price target

      TD Cowen downgraded Merck from Buy to Hold and set a new price target of $100.00 from $121.00 previously

      2/10/25 7:02:02 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRK
    Leadership Updates

    Live Leadership Updates

    See more
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components
    • Ashland Board appoints Sanat Chattopadhyay, executive vice president, Merck & Company, as new director effective November 13, 2023

      WILMINGTON, Del., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) has announced the appointment of Sanat Chattopadhyay, executive vice president of Merck & Company (NYSE:MRK) to its Board of Directors. Chattopadhyay will serve on the Board's Environmental, Health, Safety, and Quality and Governance and Nominating Committees, effective November 13, 2023.  Prior to Merck, Chattopadhyay held leadership positions at Wyeth Pharmaceuticals, Aventis, Hoechst Marion Roussel and Hoechst India. As previously announced, Jay V. Ihlenfeld who has served as a director since 2017, and Brendan M. Cummins, who joined the board in 2012 have decided not to stand for re-election at Ashland's Annua

      11/14/23 5:25:00 PM ET
      $ASH
      $MRK
      Specialty Chemicals
      Consumer Discretionary
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer

      Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer Arun Balakumaran M.D., Ph.D, appointed Chief Medical Officer of Replay to support the Company's genomic medicine and engineered NK cell therapy pipelineFormer Chief Medical Officer of allogeneic CAR-T cell company Allogene Therapeutics and seasoned industry immuno-oncology, and cell and gene therapy expert Dr. Balakumaran also appointed CMO of Syena, Replay's engineered NK cell therapy product company pioneering first-in-class engineered T-cell Receptor Natural Killer cell (TCR-NK) therapy San Diego, California and London, UK, May 18, 2023 – Replay, a genome writing company reprogramming biology by writing and deliver

      5/18/23 8:00:00 AM ET
      $ALLO
      $AMGN
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations